NXNuo Xu

Nuo Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Nuo Xu has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Chao Leng

    Tongji Hospital 9 Hepatic Surgery Center Tongji Medical College Wuhan, China

    1 shared publication
  • Chen Yang

    State Key Laboratory of Oncogenes and Related Genes, Department of Liver Surgery & Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine

    1 shared publication
  • Cun Wang

    State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute & Department of Liver Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    1 shared publication
  • Haigang Geng

    Department of Gastrointestinal Cancer Translational Research, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China

    1 shared publication
  • Haiyan Hu

    Shanghai Sixth People’s Hospital 4 Department of Oncology Shanghai Jiao Tong University School of Medicine, Shanghai, China

    1 shared publication
  • Hao Feng

    Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

    1 shared publication

Latest Publications

  • Latent Squamous Plasticity Licensed by Chromatin-State Remodeling Dictates Therapeutic Susceptibility in Cholangiocarcinoma

    by Chen Yang, Nuo Xu, Shuyi Ji, Xifu Cheng, Qian Li, Haigang Geng, Yuhan Xia, Xiujiao Shen, Zhicheng Liu, Xupeng Yang, et al.

    Adenosquamous carcinoma (ASC) in intrahepatic cholangiocarcinoma (iCCA) has long been considered rare (∼1 to 2%), yet its occurrence portends lethal disease progression. In this study, we identify latent squamous plasticity, a transcriptionally primed yet histology-silent state that is quantifiable by a squamous transition potential (STP) index. Approximately 20% to 30% of patients with iCCA can be classified as STP high and experience ASC-like dismal outcomes. Mechanistically, FOS-like 1 (FOSL1) acts as a plasticity trigger, driving a temporally ordered squamous program by reshaping the chromatin landscape. Additionally, it cooperates with p63 in an enhancer-dependent manner to dysregulate PTGS2/COX-2 expression. The resulting intratumoral prostaglandin (PG) E2 accumulation drives neutrophil-mediated FOXP3-negative type I regulatory T-cell (Tr1) polarization and predisposes STP-high tumors to immunotherapy resistance. Through a drug-repurposing screen, we identify celecoxib as a dual-function agent that counteracts latent squamous plasticity while fostering an immunopermissive state, providing a clinically actionable strategy for squamous-biased iCCA now being evaluated in a phase Ib/II trial (NCT07632235). Significance: Latent squamous plasticity defines a common yet histologically occult high-risk state in iCCA, driven by FOSL1-dependent enhancer reprogramming and coupled to a PGE2-dependent neutrophil–Tr1 immunosuppressive circuit. By integrating STP-based stratification with celecoxib repurposing, this study identifies latent squamous plasticity as a clinically actionable vulnerability to improve iCCA treatment responsiveness.